The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.

How is TNKase administered?

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.

How Was TNKase approved?

The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.

How Common Are These Strokes?

In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.

TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."

What Are The Symptoms Of Ischemic Strokes?

Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.

Other symptoms include:

• Loss of coordination or clumsiness
• Blurry vision or double vision
• Dizziness or vertigo
• Nausea and vomiting
• Neck stiffness
• Mood swings or sudden personality changes
• Confusion or agitation
• Seizures
• Memory loss (amnesia)
• Headaches which are sudden and severe
• Passing out or fainting
• Coma

Are There Any Warning Signs?

While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.

A new blood test may help identify microscopic precancerous changes linked to ovarian cancer before a tumour develops, according to a study published in Nature Medicine. Researchers found that the test could detect a molecular signal associated with an early precursor of high-grade serous ovarian cancer, one of the most common and aggressive forms of the disease.

The study, led by researchers at the Hoag Family Cancer Institute in California, identified elevated levels of an RNA molecule called Tu-Stroma in blood samples from women with a condition known as serous tubal intraepithelial carcinoma (STIC).

The findings could eventually help identify women at increased risk of developing ovarian cancer, especially those with inherited genetic mutations.

What Is STIC And How Is It Linked To Ovarian Cancer?

High-grade serous ovarian cancer mostly originates in the fallopian tubes rather than directly in the ovaries. It may begin with microscopic changes in the cells lining the fallopian tubes, known as serous tubal intraepithelial carcinoma or STIC.

These lesions are precancerous, which means they are not invasive cancer but can lead to the development of high-grade serous ovarian cancer.

STIC is difficult to detect because the abnormal cells are microscopic and cannot be identified through routine imaging. They are often discovered incidentally when women undergo surgery to remove their fallopian tubes or ovaries.

Also read: Can AI End Cancer And Alzheimer’s? Anthropic CEO Dario Amodei Predicts ‘Age Of Miracles’ Within A Decade

How Does The New Blood Test Work?

The researchers found that women with STIC had elevated levels of Tu-Stroma, an RNA molecule related to interactions between abnormal cells and surrounding healthy tissue.

The molecule is linked to a process in which cancer cells weaken neighbouring healthy cells, creating an environment that allows abnormal cells to thrive.

By measuring Tu-Stroma in blood samples, researchers investigated whether this molecular signal could identify STIC before invasive cancer develops.

In a separate validation group, the test detected STIC in 92.3% of women who had the precancerous condition and correctly identified 98.2% of healthy women.

Researchers also modelled how the test might perform in a population of women with inherited risk factors for ovarian cancer. They estimated that approximately 72% of positive results would be accurate, while a negative result would be correct nearly 100% of the time.

Also read: Why Lobular Breast Cancer Can Be Difficult To Detect On A Mammogram?

Could The Test Help Women With BRCA1 And BRCA2 Mutations?

The findings may be relevant to women carrying inherited mutations in the BRCA1 and BRCA2 genes, which increase the risk of ovarian and breast cancers significantly.

Women with these mutations may be advised to consider surgery to remove of their fallopian tubes and ovaries. While this can reduce ovarian cancer risk, it also has consequences like including the loss of fertility and the possibility of early menopause.

Dr Esha Madan, co-author of the study and a researcher at Hoag Family Cancer Institute, said, “For women at high risk, this could transform how we approach prevention.”

She added, “Today, decisions about preventive surgery are largely guided by inherited risk, without knowing whether precancerous lesions are actually present. Our discovery could eventually provide that missing biological information.”

Also read: National Cancer Awareness Day: Diagnosed With Cancer In Your 20s Or 30s? What To Know About Fertility

Can This Blood Test Be Used For Ovarian Cancer Screening?

The study analysed previously collected blood samples from women whose diagnoses were already known. It did not test the blood marker prospectively in a large population of women undergoing routine screening.

The test performed well in samples from people with confirmed conditions and may not achieve the same accuracy in the general population.

Researchers are now planning prospective studies involving women with and without inherited risk factors. These studies will assess whether Tu-Stroma can identify precancerous changes before they progress and whether the results can shape clinical decisions.

Dr Rajan Gogna, who led the research, said, “We asked a fundamentally different question: What if we could identify the earliest molecular warning signs before invasive cancer even develops?”

The discovery offers a new direction for ovarian cancer detection, shifting the focus from finding an existing tumour to identifying biological changes that may precede it.

Long known to be a key risk factor for lungs and heart, a new study now shows that long-term exposure to air pollution and fine particulate matter (PM2.5) may increase the risk of developing type 2 diabetes by 16%.

A rise of 10 micrograms per cubic metre in PM2.5 concentration was associated with a 10% to 16% increase in diabetes risk.

The findings come amid rising pollution levels in Delhi, highlighting the potential metabolic health consequences of prolonged exposure to poor air quality.

Published in the Journal of Vascular Diseases, the analysis found that air pollution is not just a cardiopulmonary concern but also a potential contributor to metabolic health problems.

What Did The Study Find?

The researchers analysed 13 major previous reviews, covering more than 200 million participant observations worldwide.

Reviews examining new diabetes cases consistently found an association between air pollution exposure and a higher risk of developing the disease.

The studies also reported higher diabetes prevalence, elevated blood sugar levels and an increased burden of related health complications.

The association was observed even among populations living in areas classified as having clean air. Since nearly everyone is exposed to outdoor air pollution, even relatively small increases in individual risk could translate into millions of additional diabetes cases worldwide.

South and East Asia are among the regions likely to face a particularly high burden.

Air Pollution Must Be Part Of Diabetes Prevention

Dr. Anoop Misra, Padma Shri, Executive Chairman and Director, Diabetes and Endocrinology, Fortis C-Doc Hospital for Diabetes and Allied Sciences, said air pollution should be recognised as a potential contributor to metabolic disorders, including diabetes, rather than viewed only as a respiratory and environmental concern.

“Air quality management must become a core part of diabetes prevention,” he said.

He also highlighted the growing public health burden in heavily polluted South Asian cities and stressed the need to integrate air quality management into diabetes prevention.

Yashendra Sethi, first author of the study, said India must focus on improving environmental conditions to protect metabolic health.

“If India wants to tackle both diabetes and pollution, we must improve metabolic health and clean up our environment. We cannot fight diabetes while ignoring the air we breathe,” Sethi said.

The researchers emphasised that diabetes prevention should be considered alongside heart and lung health when framing clean-air guidelines.

They recommended strengthening continuous air quality monitoring, tightening emissions standards and incorporating environmental factors into national healthcare policies.

Delhi Air Quality In Very Poor Category

Delhi's air quality slipped into the 'very poor' category on November 11, with the 24-hour average Air Quality Index (AQI) settling at 313. This came a day after stronger winds brought some relief, pushing the AQI into the 'poor' category.

According to the Air Quality Early Warning System (EWS) for Delhi, PM2.5 and PM10 concentrations are also expected to rise over the next two days.

Of the 58 monitoring stations that recorded data on Wednesday, one reported 'severe' air quality, 34 were in the 'very poor' category, 22 in the 'poor' category and one in the 'moderate' category.

Weeks after revealing that she had been wrongly diagnosed with multiple sclerosis (MS), Emmy-winning actor Christina Applegate is exploring whether breast implant illness could explain her chronic pain and fatigue.

Applegate has been experiencing persistent pain and fatigue, which have also affected her mobility. She gradually withdrew from public life after her MS diagnosis in 2021, as she navigated the physical and emotional toll of the condition.

However, in October, the 54-year-old actor revealed that a doctor had told her she did not have MS. She is now undergoing tests for various conditions, including autoimmune diseases and Lyme disease, to determine the cause of her debilitating symptoms.

Applegate is also considering whether her breast implants could be contributing to her health problems. Speaking on the November 10 episode of her podcast, she said her suspicions were reinforced after someone sent her a study that described breast implant illness as "presenting as MS", USA Today reported.

"I swear, over the last five years I thought, 'What if they're leaking and they're poisoning me?'" Applegate said. "So that's one that I will be looking into, because it's something I've thought about."

Christina Applegate Opens Up About Her Symptoms

Also read: Christina Applegate Reveals Multiple Sclerosis Misdiagnosis: Why The Disease Is Hard To Diagnose

Applegate said she is struggling to understand what is causing her persistent pain and fatigue, describing how the symptoms have affected her mobility.

"I'm trying to figure out what's wrong with me; of course I know about these things," she said, referring to the messages she receives from people suggesting possible diagnoses.

She added that the number of possible explanations had become overwhelming.

"It's overwhelming because there's so many different things that could be going on, and this pain stuff – I don't know what's going on in my joints, but I can't move my right shoulder at all now. I can't lift my arm," she said.

In an earlier podcast episode in October, Applegate spoke emotionally about the uncertainty surrounding her health after learning that she did not have MS.

"I'm back at square one – that I don't know what's going on with me," she said.

Despite the news, Applegate said her symptoms have not improved.

“I haven’t gotten better. I still have to use wheelchairs when I go to the doctor’s office. I can’t walk from the car to the room. I’m still in this. Nothing magical happened when she said, ‘You don’t have MS.’ Nothing magical happened.”

Christina Applegate's Breast Cancer And Implant History

Applegate was diagnosed with early-stage breast cancer in 2008 and underwent a double mastectomy, followed by breast reconstruction.

She also discovered that she carries a BRCA1 gene mutation, which increases the risk of developing breast and ovarian cancers.

The actor has previously spoken about her breast implants, saying she was "way overdue for having [the implants] replaced."

What Is Breast Implant Illness?

Breast implant illness (BII) is a term used to describe a range of systemic symptoms that some people report experiencing after receiving breast implants.

The US Food and Drug Administration (FDA) has highlighted several potential complications associated with breast implants, including capsular contracture, implant rupture, certain cancers and symptoms collectively described as breast implant illness.

Reported BII symptoms include:

• Persistent fatigue
• Memory and concentration problems, often described as brain fog
• Joint and muscle pain
• Hair loss
• Weight changes
• Anxiety and depression

However, BII is not a formally recognised medical diagnosis. The FDA notes that there are no specific tests or established diagnostic criteria to define or identify the condition.

While some people report improvements in symptoms after implant removal, the relationship between breast implants and these systemic symptoms remains an area of ongoing research. Applegate's concerns about a possible connection with her symptoms have not yet been medically established.